Send to

Choose Destination
Muscle Nerve. 2009 Feb;39(2):137-43. doi: 10.1002/mus.21213.

Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients.

Author information

University of Texas Health Science Center, 7703 Floyd Curl Drive, Mail Code 7883, San Antonio, Texas 78229-3900, USA.


Twenty ALS patients with sialorrhea refractory to medical therapy were enrolled in this double-blind, randomized study to receive either 2,500 U of botulinum toxin type B (BTxb) or placebo into the bilateral parotid and submandibular glands using electromyographic guidance. Patients who received BTxb reported a global impression of improvement of 82% at 2 weeks compared to 38% of those who received placebo (P < 0.05). This significant effect was sustained at 4 weeks. At 12 weeks, 50% of patients who received BTxb continued to report improvement compared to 14% of those who received placebo. There were no significant adverse events, including dysphagia, in the BTxb group, and there was no significant increase in the rate of decline of vital capacity.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center